Results for mucopolysaccharidosis translation from English to Slovak

mucopolysaccharidosis type iii
mukopolysacharidóza, iii. typ

naglazyme is used to treat patients with mps vi disease (mucopolysaccharidosis vi).
naglazyme sa používa na liečbu pacientov s mps vi chorobou (mukopolysacharidóza vi).

naglazyme is used to treat patients who have mucopolysaccharidosis vi (mps vi or maroteaux-lamy syndrome).
liek naglazyme sa používa na liečbu pacientov s mukopolysacharidózou vi (mps vi alebo aj maroteaux-lamyho syndróm).

hunter syndrome, which is also known as mucopolysaccharidosis ii, is a rare, inherited disease that primarily affects male patients.
hunterov syndróm, známy aj ako mukopolysacharidóza ii, je zriedkavá dedičná choroba, ktorá postihuje hlavne mužov.

elaprase is indicated for the long-term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).
elaprase je indikovaný pre dlhodobú terapiu pacientov s hunterovým syndrómom (mukopolysacharidóza ii, mps ii).

elaprase is used as enzyme replacement therapy to treat hunter syndrome (mucopolysaccharidosis ii) when the level of iduronate-2-sulfatase in the body is lower than normal.
elaprase sa používa na terapiu náhrady enzýmu na liečbu hunterovho syndrómu (mukopolysacharidóza ii), keď je úroveň iduronát- 2- sulfatázy v tele nižšia ako normálna.

naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis vi (mps vi; n-acetylgalactosamine 4-sulfatase deficiency; maroteaux-lamy syndrome) (see section 5.1).
naglazyme je indikovaný na dlhodobú enzýmovú substitučnú liečbu u pacientov s potvrdenou diagnózou mukopolysacharidózy vi (mps vi; nedostatok n-acetylgalaktozamín 4-sulfatázy; maroteaux-lamyho syndróm) (pozri časť 5.1).